Ilan Kaufthal

Mar 05, 2015

Ilan Kaufthal was elected to the board of Bio-Reference Laboratories, CEO Marc Grodman said this week. Kaufthal fills the vacancy created by the death of Gary Lederman in November. Kaufthal retired from Bear, Stearns in 2008 as vice chairman of investment banking and has served on several company boards since.

More Like This

Oct 19, 2017

Douglas Berthiaume, Christopher O'Connell

Douglas Berthiaume is retiring as chairman of Waters' board, effective Dec. 31, 2017. Waters President and CEO Christopher O'Connell was elected the firm's new chairman. Berthiaume became president and CEO of Waters in 1994, when it split from Millipore, and he retired as the company's CEO in 2015. He took over as chairman of the firm in 1996. 

Oct 18, 2017

Carlos Bustamante

HumanCode has appointed Carlos Bustamante to its scientific advisory board. Bustamante is currently a professor of computational genomics and biomedical informatics at Stanford University. He will provide scientific guidance to the company following the launch of its BabyGlimpse DNA app for couples to explore the genetics of potential offspring.

Oct 18, 2017

Olivier Elemento and Anshul Kundaje

Freenome has announced the formation of its scientific advisory board including inaugural members Olivier Elemento and Anshul Kundaje.

Elemento is director of the Englander Institute for Precision Medicine, head of the Cancer Systems Biology Laboratory, and associate professor of computational genomics in computational biomedicine at Weill Cornell Medical College. He also serves as co-assistant dean for scientific computing, associate director of the Institute for Computational Biomedicine, and co-chair of the Genetics, Epigenetics and Systems Biology Program at the Meyer Cancer Center. 

Kundaje is an assistant professor of genetics and computer science at Stanford University, focused on computational regulatory genomics. He previously led integrative analysis efforts for the ENCODE Project and the Roadmap Epigenomics Project. 

According to Freenome, the new SAB will work closely with the company's management team to advance the development of the firm's technology platform and commercial disease screening products.

Oct 17, 2017

Kathryn McKenzie

Kathryn McKenzie has been appointed principal accounting officer and vice president of finance at NeoGenomics. Previously, she worked for Chico's FAS in several roles including assistant controller and director of financial reporting and treasury. She was also previously an audit manager for Ernst and Young.

Oct 13, 2017

Fred Hirsch

Biocept said that Fred Hirsch has joined its clinical advisory board. Hirsch is a professor of medicine and pathology at the University of Colorado Cancer Center.

Oct 11, 2017

Thomas Grogan

Thomas Grogan has joined the board of directors of ReadCoor. He is professor emeritus of pathology at the University of Arizona College of Medicine and a scientific advisor to Ventana Medical Systems, which he founded, and Roche Tissue Diagnostics. 

Oct 11, 2017

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

Oct 10, 2017

Andrea Bodnar

Andrea Bodnar has joined the Gloucester Marine Genomics Institute as its first scientific director. Bodnar recently served as a senior scientist in the molecular lab of the Bermuda Institute of Ocean Science, and she previously held senior scientist posts in the oncology department at Hoffman-La Roche and at Geron. She will lead the non-profit institute's genomics-driven marine research efforts.

Oct 10, 2017

Greg Yap

Greg Yap is joining Menlo Ventures as a partner to lead investments in health, medical, and life science technologies. Yap was most recently an entrepreneur-in-residence at Illumina Ventures, where he focused on new genomics investments, and also co-founded and served as CEO of PyrAmes, a digital health company. Previously Yap was CEO and co-founder of protein analysis firm Biodesy. He has also held senior roles at Roche/Ventana and Affymetrix.

Oct 10, 2017

John Kenny

John Kenny has been appointed CEO of Meridian Bioscience, effective Oct. 9. He replaces John Kraeutler who is stepping down to become executive chairman. Kraeutler announced in May his plans to resign from the company as CEO. Kenny also was appointed to Meridian's board, effective Oct. 9. Kenny was most recently senior vice president, general manager, North America at Siemens Healthcare. He has also held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics.

Oct 09, 2017

California Precision Medicine Advisory Committee

California Gov. Edmund "Jerry" Brown has created the Governor's Advisory Committee on Precision Medicine and name some well-known figures to the 14-member panel. The committee will advise the governor's office on all matters related to precision medicine and make recommendations for statewide policy. Founding members are: 

  • Tomás Aragón, health officer of the City and County of San Francisco
  • Atul Butte, principal investigator of the California Initiative to Advance Precision Medicine at UC San Francisco
  • John Carpten, chair of the Department of Translational Genomics at the University of Southern California Keck School of Medicine
  • Jay Gellert, former president and CEO of Health Net
  • Kim Goodwin, author of "Designing for the Digital Age"
  • Stephen Lockhart, chief medical officer of Sutter Health
  • Kelsey Martin, dean of the David Geffen School of Medicine at UCLA
  • Mary Maxon, associate laboratory director for biosciences at Lawrence Berkeley National Laboratory
  • Jessica Mega, chief medical officer of Verily Life Sciences
  • Jill Mesirov, associate vice chancellor for computational health at UC San Diego School of Medicine
  • Frederick Meyers, associate dean for precision medicine at UC Davis Health
  • Arnold Milstein, director of the Clinical Excellence Research Center at Stanford University
  • Hakan Sakul, vice president of diagnostics at Pfizer
  • Sue Siegel, CEO of GE Ventures. 
Oct 05, 2017

Mark Lewis

Mark Lewis has become CEO of Swift Biosciences, replacing Tim Harkins. Most recently, he held senior vice president roles in product development, general management, and customer support at Illumina. Previously, Lewis held R&D, commercial, and general management roles at various other companies, including BD Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. He holds a BA in biology from the University of California, San Diego.

Oct 03, 2017

Alan Copperman

Alan Copperman has joined health information firm Sema4 as its chief medical officer. Copperman is director of the division of reproductive endocrinology and infertility, and vice chairman of the department of obstetrics, gynecology, and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is managing partner at Reproductive Medicine Associates of New York. 

Oct 03, 2017

Jeffrey Rona

Jeffrey Rona has resigned from his position as CFO of Great Basin Scientific, effective October 6, 2017.

Oct 03, 2017

Paul Eros

Novacyt has appointed Paul Eros as commercial director, effective Nov. 1. Eros joins Novacyt from DiaSorin, where he was VP of molecular marketing for more than five years. He has also worked for Becton Dickinson and Roche Diagnostics

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.